Clinical Alzheimer's disease (AD) treatment faces dilemmas in low blood‐brain barrier (BBB) penetration and complex interaction mechanisms between Aβ deposits and phosphorylated Tau. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.